ES2970074T3 - Inhibidor de ATR y su aplicación - Google Patents

Inhibidor de ATR y su aplicación

Info

Publication number
ES2970074T3
ES2970074T3 ES19750376T ES19750376T ES2970074T3 ES 2970074 T3 ES2970074 T3 ES 2970074T3 ES 19750376 T ES19750376 T ES 19750376T ES 19750376 T ES19750376 T ES 19750376T ES 2970074 T3 ES2970074 T3 ES 2970074T3
Authority
ES
Spain
Prior art keywords
application
atr inhibitor
atr
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19750376T
Other languages
English (en)
Inventor
Wenyuan Qian
Jian Wang
Jie Li
Jian Li
Shuhui Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Biocity Biopharmaceutics Co Ltd
Original Assignee
Wuxi Biocity Biopharmaceutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biocity Biopharmaceutics Co Ltd filed Critical Wuxi Biocity Biopharmaceutics Co Ltd
Application granted granted Critical
Publication of ES2970074T3 publication Critical patent/ES2970074T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES19750376T 2018-02-07 2019-02-02 Inhibidor de ATR y su aplicación Active ES2970074T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810124494 2018-02-07
CN201811361512 2018-11-15
PCT/CN2019/074578 WO2019154365A1 (zh) 2018-02-07 2019-02-02 一种atr抑制剂及其应用

Publications (1)

Publication Number Publication Date
ES2970074T3 true ES2970074T3 (es) 2024-05-24

Family

ID=67548753

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19750376T Active ES2970074T3 (es) 2018-02-07 2019-02-02 Inhibidor de ATR y su aplicación

Country Status (19)

Country Link
US (1) US11434232B2 (es)
EP (1) EP3753937B1 (es)
JP (1) JP7290651B2 (es)
CN (1) CN111712499B (es)
AU (1) AU2019217388C1 (es)
BR (1) BR112020016020A8 (es)
CA (1) CA3090330A1 (es)
DK (1) DK3753937T3 (es)
ES (1) ES2970074T3 (es)
FI (1) FI3753937T3 (es)
HR (1) HRP20240161T1 (es)
IL (1) IL276489B1 (es)
LT (1) LT3753937T (es)
PL (1) PL3753937T3 (es)
PT (1) PT3753937T (es)
RS (1) RS65147B1 (es)
SG (1) SG11202007485PA (es)
SI (1) SI3753937T1 (es)
WO (1) WO2019154365A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020244613A1 (zh) * 2019-06-06 2020-12-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
BR112022001393A2 (pt) * 2019-08-06 2022-03-22 Wuxi Biocity Biopharmaceutics Co Ltd Forma cristalina do inibidor de atr e seu uso
WO2021233376A1 (zh) * 2020-05-20 2021-11-25 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
AU2021282122B2 (en) * 2020-05-29 2023-09-21 Wuxi Life Fountain Biotech Co., Ltd Fluoropyrrolopyridine compound and application thereof
KR20230043109A (ko) * 2020-06-24 2023-03-30 아스트라제네카 유케이 리미티드 항체-약물 접합체 및 atr 억제제의 조합
CN116134022A (zh) * 2020-07-03 2023-05-16 上海德琪医药科技有限公司 Atr抑制剂和其用途
CN116178366A (zh) * 2021-11-26 2023-05-30 深圳市瓴方生物医药科技有限公司 氟代吡啶并吡咯类化合物的晶型及其制备方法
WO2023131234A1 (en) * 2022-01-06 2023-07-13 Shanghai Antengene Corporation Limited Crystalline forms of an atr inhibitor
WO2023215133A1 (en) * 2022-05-02 2023-11-09 AcuraStem Incorporated Pikfyve kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093981A1 (en) 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US20110053923A1 (en) * 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
US9481670B2 (en) 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN111655688B (zh) * 2017-09-08 2023-09-29 蓝谷制药有限责任公司 经取代的吡咯并吡啶类化合物作为atr抑制剂

Also Published As

Publication number Publication date
HRP20240161T1 (hr) 2024-04-12
EP3753937A4 (en) 2021-07-07
EP3753937A1 (en) 2020-12-23
JP2021512908A (ja) 2021-05-20
AU2019217388C1 (en) 2024-03-07
BR112020016020A2 (pt) 2020-12-08
IL276489A (en) 2020-09-30
DK3753937T3 (da) 2024-02-12
JP7290651B2 (ja) 2023-06-13
SG11202007485PA (en) 2020-09-29
BR112020016020A8 (pt) 2023-04-25
PT3753937T (pt) 2024-02-06
LT3753937T (lt) 2024-02-26
CN111712499A (zh) 2020-09-25
RU2020128324A (ru) 2022-03-09
AU2019217388A1 (en) 2020-09-03
PL3753937T3 (pl) 2024-04-02
AU2019217388B2 (en) 2023-11-09
SI3753937T1 (sl) 2024-03-29
CA3090330A1 (en) 2019-08-15
RU2020128324A3 (es) 2022-03-09
IL276489B1 (en) 2024-05-01
EP3753937B1 (en) 2024-01-10
US20200399260A1 (en) 2020-12-24
CN111712499B (zh) 2023-06-02
WO2019154365A1 (zh) 2019-08-15
FI3753937T3 (fi) 2024-01-31
RS65147B1 (sr) 2024-02-29
US11434232B2 (en) 2022-09-06

Similar Documents

Publication Publication Date Title
ES2970074T3 (es) Inhibidor de ATR y su aplicación
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
DK3610005T3 (da) Peptidligase og anvendelse deraf
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
MA52812A (fr) Inhibiteurs de sarm1
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3668955T3 (da) Korrosionsinhibitor
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA49006A (fr) Inhibiteurs d'ip6k
MA49905A (fr) Polyesteramines et polyesterquats
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
ZA202102192B (en) Fgfr4 inhibitor and use thereof
MA52809A (fr) Inhibiteurs de sarm1
MA51611A (fr) Inhibiteurs de pi4kiiibêta
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
MA52813A (fr) Inhibiteurs de sarm1
DK3280405T3 (da) Inhibitorer og anvendelser deraf
DK3714070T3 (da) Hidtil ukendt cip2a-variant og anvendelser deraf
DK3710457T3 (da) Immunproteasomhæmmere
DK3601450T3 (da) Belægningssammensætning og anvendelse deraf
DK3720840T3 (da) Cathepsinhæmmere